Real world data with secukinumab for moderate-to-severe plaque psoriasis: Evaluation of safety, efficacy and drug survival in 50 patients

2019 ◽  
Vol 81 (4) ◽  
pp. AB114
Keyword(s):  
Real World ◽  
Plaque Psoriasis ◽  
Real World Data ◽  
Severe Plaque Psoriasis ◽  
World Data ◽  
Drug Survival

scholarly journals Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0244620
Author(s):  
Yu-Chen Chen ◽  
Yi-Ting Huang ◽  
Chao-Chun Yang ◽  
Edward Chia-Cheng Lai ◽  
Cheng-Han Liu ◽  
...  
Keyword(s):  
Clinical Data ◽  
Real World ◽  
Plaque Psoriasis ◽  
Severity Index ◽  
Tertiary Hospital ◽  
Biological Agents ◽  
Efficacy And Safety ◽  
Real World Data ◽  
Severe Plaque Psoriasis ◽  
Asian Populations

Background Real-world clinical data on psoriasis patients receiving different biological agents is needed, especially in Asian populations. Objectives Our aim is to compare and analyze the efficacy and safety profile of four biological agents (etanercept, adalimumab, ustekinumab and secukinumab) in a real-world setting in Taiwan. Methods We retrospectively analyzed the clinical data of all patients with moderate-to-severe plaque psoriasis (Psoriasis Area and Severity Index (PASI) ≥ 10) who received etanercept, adalimumab, ustekinumab or secukinumab between January 2011 and December 2018 in a tertiary hospital in Taiwan. Results A total of 119 treatment episodes in 75 patients were included in this study. Ustekinumab was used in 49 treatment episodes, followed by secukinumab in 46 treatment episodes, adalimumab in 14 treatment episodes and etanercept in 10 treatment episodes. The proportion of the biologic-naïve was highest in etanercept (100%) and lowest in secukinumab (23.9%). The PASI-75, -90 and -100 were the highest in secukinumab (91.3%, 82.6%, 41.3%, respectively), followed by ustekinumab (79.6%, 44.9%, 16.3%), adalimumab (64.3%, 28.6%, 7.1%) and etanercept (50.0%, 30.0%, 0%). The rate of adverse events that required treatment was highest for secukinumab (15.2%), followed by adalimumab (14.3%), ustekinumab (8.2%), and etanercept (0%), including 4 cases of infections, 2 cases of cardiovascular diseases and 4 cases of cancers. Conclusions This real world data showed differential efficacy and safety of the four biological agents.

Real-world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis

2018 ◽  
Vol 30 (4) ◽  
pp. 383-386 ◽  
Author(s):  
Chika Ohata ◽  
Bungo Ohyama ◽  
Fumi Kuwahara ◽  
Eri Katayama ◽  
Takekuni Nakama
Keyword(s):  
Real World ◽  
Plaque Psoriasis ◽  
Japanese Patients ◽  
Efficacy And Safety ◽  
Real World Data ◽  
World Data

Abstract #946: Assessment of Acromegaly Patients with and Without Diabetes Treated with Lanreotide Depot: 2-Year Real World Data

2016 ◽  
Vol 22 ◽  
pp. 219
Author(s):  
Roberto Salvatori ◽  
Olga Gambetti ◽  
Whitney Woodmansee ◽  
David Cox ◽  
Beloo Mirakhur ◽  
...  
Keyword(s):  
Real World ◽  
Real World Data ◽  
World Data
Sign in / Sign up

Export Citation Format

Share Document